Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma?
β Scribed by Alessandro Fornari; Roberto Piva; Roberto Chiarle; Domenico Novero; Giorgio Inghirami
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 341 KB
- Volume
- 27
- Category
- Article
- ISSN
- 0278-0232
- DOI
- 10.1002/hon.897
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Anaplastic large cell lymphoma (ALCL) is a subtype of peripheral Tβcell lymphoma (PTCL) first described in 1985 as a lymphoid malignancy characterized by marked cellular pleomorphism, propensity to grow cohesively, tendency to invade lymph node sinuses and diffuse expression of CD30 1. The discovery of the t(2;5), involving the anaplastic lymphoma kinase (ALK) gene on chromosome 2 and the nucleophosmin (NPM) gene on chromosome 5 in the majority of systemic ALCL, has soon pointed out that ALCL is a clinically and biologically heterogeneous disease. While ALKβpositive (ALK+) ALCL is usually characterized by onset in children and young adults and better prognosis, epidemiology, poor outcome and possibly genetic defects of ALKβnegative (ALKβ) ALCL suggest that this neoplasms should be considered an independent pathological entity. The aim of this review is to illustrate clinical features, histology, immunophenotype, genetics and biology of ALCL and discuss possible relationship(s) among different TβnonβHodgkin lymphoma (TβNHL). Copyright Β© 2009 John Wiley & Sons, Ltd.
π SIMILAR VOLUMES
In the last two decades posttransplant lymphoproliferative disorders (PTLDs) have been recognized as a complication of organ transplantation with immunosuppression. The reported incidence of PTLDs in renal transplant patients ranges between 0.3-3% (Birkeland et al., Transplantation 1999;67:876-881).
To determine the significance of the t(2;5)(p23;q35) translocation in nodal and extranodal anaplastic large cell lymphoma (ALCL), we performed cytogenetic, molecular genetic, and immunohistochemical analyses of tumor tissues from 11 patients with CD30Ο© ALCL. Three of five patients with nodal ALCL ha